Neurodegenerative Diseases Therapeutics Market to Witness Significant Growth from 2024 to 2028

The Neurodegenerative Diseases Therapeutics Market is poised for substantial expansion, with its size forecasted to increase by USD 21.29 billion at a CAGR of 8.51% between 2023 and 2028. The strong drug development pipeline and the rising aging population are key drivers, while the lack of disease-modifying therapies presents a challenge. Advancements in Artificial Intelligence (AI), Internet of Things (IoT), micro-electromechanical systems (MEMS), sensors, and robotics are expected to transform patient care. The integration of smart homes and virtual assistants is improving disease management, particularly in Alzheimer’s therapies, Parkinson’s drugs, Multiple sclerosis treatments, and Huntington’s disease cures. The growing focus on ALS therapeutics and innovative approaches such as gene therapy, monoclonal antibodies, and biomarkers is driving industry evolution. Additionally, increasing investments in clinical trials for neurodegenerative disorders are paving the way for advanced treatment solutions

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Indication

• Multiple Sclerosis (MS)

• Alzheimer’s Disease

• Parkinson’s Disease

• Huntington’s Disease

• Others

By Geography

• North America

  • Canada

  • US

• Europe

  • Germany

  • UK

• Asia

  • China

  • Japan

• Rest of the World (ROW)

Segment Insights

By Indication Insights

The multiple sclerosis (MS) segment is expected to experience significant growth. In the US, approximately 1 million people suffer from MS, while globally, 2.9 million individuals are diagnosed. To meet the growing demand, pharmaceutical companies are focusing on research and development. Advanced technologies such as AI, IoT, MEMS, robotics, and vision technologies are being leveraged to develop innovative treatments.

Commercialization of novel drugs, including Tecfidera, Aubagio, Lemtrada, Gilenya, and Tysabri, is anticipated to propel market expansion. The multiple sclerosis segment was valued at USD 14.44 billion in 2018, with steady growth projected throughout the forecast period.

Regional Market Trends

North America (40% Market Contribution in 2023)

• The largest regional market due to the presence of key players.

• Significant product offerings include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for MS treatment.

• Companies like Neuraly (Maryland-based) invested USD 36 million in drug development for neurodegenerative diseases using AI, IoT, MEMS, robotics, and smart speakers.

Market Dynamics

Key Market Drivers

• Strong Drug Development Pipeline

  • The increasing prevalence of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and MS is driving research.

  • By March 2024, one-third of the global population is affected by neurological conditions, leading to increased demand for therapeutics.

  • 164 clinical trials are currently assessing 127 drugs for Alzheimer’s disease, reflecting significant R&D investments.

Market Trends

• Aging Population Driving Market Growth

  • According to the WHO, the 60+ age group will rise from 12% in 2015 to 22% by 2050.

  • Sub-Saharan Africa is witnessing increased cases of dementia and Parkinson’s disease.

  • Advancements in AI, robotics, and home automation are enhancing care for neurodegenerative disease patients.

Market Challenges

• Lack of Disease-Modifying Therapies

  • While symptomatic relief is available, there are no disease-modifying treatments for several neurodegenerative conditions.

  • Huntington’s disease, caused by a mutation in the huntingtin gene, currently lacks an effective cure.

  • Compatibility with smart home technology and anti-fall sensors is crucial for patient safety.

Market Research Overview

The Neurodegenerative Diseases Therapeutics Market is evolving rapidly, driven by advancements in drug development pipelines, precision medicine, and regenerative therapies. The demand for disease-modifying therapies is pushing research into monoclonal antibodies, gene therapy, stem cell therapy, and neuroprotective agents. Emerging therapeutics, such as antisense oligonucleotides, RNA interference, and enzyme inhibitors, are also gaining traction. Biomarkers, clinical trials, and FDA approvals are crucial in shaping the future of the industry.

Get more details by ordering the complete report

Key Players

• AB Science SA

• AbbVie Inc.

• Acadia Pharmaceuticals Inc.

• Biogen Inc.

• F. Hoffmann-La Roche Ltd.

• H Lundbeck AS

• Mitsubishi Chemical Corp.

• Novartis AG

• Sanofi SA

• Teva Pharmaceutical Industries Ltd.

These companies are leveraging strategic alliances, mergers & acquisitions, geographic expansion, and product innovations to strengthen their market positions

Research Analysis Overview

The global neurodegenerative disease therapeutics landscape is influenced by innovations in biologics, peptide therapeutics, neurotransmitter modulation, and anti-inflammatory agents. The challenges of cognitive decline, neuroinflammation, oxidative stress, mitochondrial dysfunction, and blood-brain barrier penetration are being addressed through precision medicine and advanced drug formulations. Companies are investing in pipeline drugs, orphan drugs, and regenerative medicine, ensuring a dynamic competitive landscape.